SIRI Predicts Survival in Lung Cancer Patients Undergoing Immunotherapy
Author Information
Author(s): Tang Chunhan, Zhang Min, Jia Hongyuan, Wang Tianlei, Wu Hongwei, Xu Ke, Ren Tao, Liang Long
Primary Institution: Chengdu Medical College
Hypothesis
This study aims to evaluate the prognostic value of the Systemic Inflammation Response Index (SIRI) in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1 inhibitors.
Conclusion
SIRI is an important independent predictor of early progression in advanced NSCLC patients treated with PD-1 inhibitors.
Supporting Evidence
- Patients with high post-SIRI levels had a 2.48-fold increased risk of disease progression.
- Post-SIRI was identified as an independent risk factor for overall survival.
- The nomogram model showed good predictive accuracy for patient prognosis.
- Median progression-free survival was 12.9 months and overall survival was 19.9 months.
- Internal validation indicated good agreement between predicted and observed survival rates.
Takeaway
Doctors can use a blood test called SIRI to help figure out how well lung cancer patients might do with a specific treatment.
Methodology
A retrospective study analyzed blood markers and survival outcomes in advanced NSCLC patients treated with anti-PD-1 drugs.
Potential Biases
Potential biases may arise from the retrospective nature and single-center data collection.
Limitations
The study is retrospective, has a small sample size, lacks external validation, and is based on single-center data.
Participant Demographics
The majority of participants were male (88.5%), with a history of smoking (76.4%) and advanced stage IV disease (67.6%).
Statistical Information
P-Value
P < 0.001
Confidence Interval
95% CI: 0.693–0.747
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website